Sexual Dysfunctions, PsychologicalPhase 3NCT00360555

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

A Phase 3 study testing flibanserin, flibanserin 50mg and flibanserin 100mg in people with Sexual Dysfunctions, Psychological, run by Sprout Pharmaceuticals, Inc at 77 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group. Read more about this study

Who is it for?: Ages 18 to 55 years, women only
Conditions the study is for: Sexual Dysfunctions, Psychological
What is being tested?: flibanserin, flibanserin 50mg and flibanserin 100mg
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 1,584 participants
Where: 77 sitesin 2 countries
Study dates: Jul 2006to Mar 2008
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 55 years
Women only
No healthy volunteers
Adult

Who may be able to join

Women who are 18 years of age and older.
Premenopausal women having regular menstrual periods who have HSDD (decreased sexual desire), generalized acquired type, according to DSM IV-TR criteria.
Patient must meet minimum cut-off scores on questionnaires relating to sexual functioning and sexual distress.
Patients must be willing to try to have sexual activity (e.g., any act involving direct genital stimulation) at least once monthly.
Patients must be willing and able to use an electronic diary on a daily basis (e.g., have access to a working land line telephone for daily data transmissions).
At the Baseline Visit, patients must have complied with eDiary use adequately.

Show all 12Show fewer

Patients must be in a stable, monogamous, heterosexual relationship that is secure and communicative, for at least 1 year prior to the Screen Visit. The partner is expected to be physically present at least 50% of each month.
Patients must have used a medically acceptable method of contraception for at least 3 months before the Baseline Visit (Visit 2) and continue to use that medically acceptable method of contraception during the trial.
In the investigators opinion, patients must be reliable, honest, compliant, and agree to co-operate with all trial evaluations as well as to be able to perform them.
Patients must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must have sufficient understanding to communicate effectively with the investigator, and be willing to discuss their sexual functioning with the investigative staff.
Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Screen Visit.
A score of 15 or higher on the FSDS-R at the screen Visit.

Who cannot join

Patients who have taken any medication noted in the protocols List of Prohibited Medications within 30 days before screening.
Patients whose sexual function was affected (enhanced or worsened) in the investigators opinion by any medication within 30 days before the Screen Visit and anytime prior to the Baseline Visit.
Patients with a history of drug dependence or abuse within the past one year.
Patients with a history of multiple severe reactions (i.e., allergic or oversensitivity to usual doses) to drugs that affect the brain.
Patients with a history of participation in a trial of another investigational medication within one month prior to the Screen Visit, or participation in any previous clinical trial of flibanserin.
Patients who meet accepted diagnostic criteria for sexual disorders that would interfere with improvement in HSDD (sexual aversion, substance-induced sexual problems, urge to live as a man, etc.

Show all 14Show fewer

Patients who indicate that their sexual partner has inadequately treated sexual problems that could interfere with the patients response to treatment.
Patients who have entered the menopausal transition or menopause or have had a hysterectomy.
Patients with findings at the Screen Visit of infection, inflammation, undue tenderness, or shrinkage (atrophy) of the female organs.
Patients who are breast feeding or have breastfed within the last 6 months prior to the Baseline Visit.
Patients who are pregnant or have been pregnant within the last 6 months prior to the Baseline Visit.
Patients with a history of Major Depressive Disorder within 6 months prior the Screen Visit, a score indicating depression on a depression scale, a history of suicide attempt, or current suicidal ideation evident at the Screen or Baseline Visit.
Patients with a history of any other psychiatric disorders that could impact sexual function, risks patients safety, or may impact compliance.
Patients who have started psychotherapy

Trial locations and contacts

77 sites in 2 countries.

Country

City, postcode or hospital

77 sites in 2 countries

United States64 sites

511.75.01065 Boehringer Ingelheim Investigational Site
Aurora, Colorado
511.75.01013 Boehringer Ingelheim Investigational Site
Austin, Texas
511.75.01069 Boehringer Ingelheim Investigational Site
Beachwood, Ohio
511.75.01017 Boehringer Ingelheim Investigational Site
Berkeley, California
511.75.01043 Boehringer Ingelheim Investigational Site
Bingham Farms, Michigan
511.75.01015 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
511.75.01037 Boehringer Ingelheim Investigational Site
Chapel Hill, North Carolina
511.75.01007 Boehringer Ingelheim Investigational Site
Charlottesville, Virginia
511.75.01025 Boehringer Ingelheim Investigational Site
Chaska, Minnesota
511.75.01024 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri
511.75.01023 Boehringer Ingelheim Investigational Site
Chicago, Illinois
511.75.01012 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
511.75.01071 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
511.75.01038 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
511.75.01048 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
511.75.01067 Boehringer Ingelheim Investigational Site
Columbia, South Carolina
511.75.01061 Boehringer Ingelheim Investigational Site
Columbus, Ohio
511.75.01066 Boehringer Ingelheim Investigational Site
Coral Gables, Florida
511.75.01027 Boehringer Ingelheim Investigational Site
Dallas, Texas
511.75.01014 Boehringer Ingelheim Investigational Site
Encinitas, California
511.75.01003 Boehringer Ingelheim Investigational Site
Englewood, Colorado
511.75.01052 Boehringer Ingelheim Investigational Site
Eugene, Oregon
511.75.01042 Boehringer Ingelheim Investigational Site
Fair Oaks, California
511.75.01040 Boehringer Ingelheim Investigational Site
Fort Meyers, Florida
511.75.01031 Boehringer Ingelheim Investigational Site
Fort Wayne, Indiana
511.75.01044 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
511.75.01001 Boehringer Ingelheim Investigational Site
Gainesville, Florida
511.75.01070 Boehringer Ingelheim Investigational Site
Greenville, South Carolina
511.75.01062 Boehringer Ingelheim Investigational Site
Hollywood, Florida
511.75.01011 Boehringer Ingelheim Investigational Site
Houston, Texas
511.75.01022 Boehringer Ingelheim Investigational Site
Irvine, California
511.75.01018 Boehringer Ingelheim Investigational Site
Jenkintown, Pennsylvania
511.75.01009 Boehringer Ingelheim Investigational Site
Kansas City, Missouri
511.75.01064 Boehringer Ingelheim Investigational Site
Knoxville, Tennessee
511.75.01005 Boehringer Ingelheim Investigational Site
La Jolla, California
511.75.01050 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
511.75.01060 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
511.75.01063 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
511.75.01059 Boehringer Ingelheim Investigational Site
Medfod, Oregon
511.75.01036 Boehringer Ingelheim Investigational Site
Middleton, Wisconsin
511.75.01028 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.75.01049 Boehringer Ingelheim Investigational Site
Nashville, Tennessee
511.75.01004 Boehringer Ingelheim Investigational Site
New Brunswick, New Jersey
511.75.01057 Boehringer Ingelheim Investigational Site
Norfolk, Virginia
511.75.01032 Boehringer Ingelheim Investigational Site
Ocala, Florida
511.75.01047 Boehringer Ingelheim Investigational Site
Orlando, Florida
511.75.01073 Boehringer Ingelheim Investigational Site
Palm Bay, Florida
511.75.01051 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
511.75.01021 Boehringer Ingelheim Investigational Site
Portland, Oregon
511.75.01046 Boehringer Ingelheim Investigational Site
Richmond, Virginia
511.75.01053 Boehringer Ingelheim Investigational Site
Sacremento, California
511.75.01055 Boehringer Ingelheim Investigational Site
San Antonio, Texas
511.75.01045 Boehringer Ingelheim Investigational Site
San Diego, California
511.75.01006 Boehringer Ingelheim Investigational Site
Sandy Springs, Georgia
511.75.01035 Boehringer Ingelheim Investigational Site
Sarasota, Florida
511.75.01019 Boehringer Ingelheim Investigational Site
Seattle, Washington
511.75.01010 Boehringer Ingelheim Investigational Site
South Miami, Florida
511.75.01041 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
511.75.01033 Boehringer Ingelheim Investigational Site
Tampa, Florida
511.75.01020 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma
511.75.01068 Boehringer Ingelheim Investigational Site
Waco, Texas
511.75.01030 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
511.75.01002 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
511.75.01054 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina

Other trials in United States

Canada13 sites

511.75.02010 Boehringer Ingelheim Investigational Site
Barrie, Ontario
511.75.02008 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia
511.75.02011 Boehringer Ingelheim Investigational Site
London, Ontario
511.75.02005 Boehringer Ingelheim Investigational Site
Mount Pearl, Newfoundland and Labrador
511.75.02002 Boehringer Ingelheim Investigational Site
North Vancouver, British Columbia
511.75.02001 Boehringer Ingelheim Investigational Site
Ottawa, Ontario
511.75.02012 Boehringer Ingelheim Investigational Site
Québec, Quebec
511.75.02014 Boehringer Ingelheim Investigational Site
Québec, Quebec
511.75.02003 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
511.75.02009 Boehringer Ingelheim Investigational Site
Sherbrooke, Quebec
511.75.02007 Boehringer Ingelheim Investigational Site
Toronto, Ontario
511.75.02013 Boehringer Ingelheim Investigational Site
Trois-Rivières, Quebec
511.75.02004 Boehringer Ingelheim Investigational Site
Woodstock, New Brunswick

Other trials in Canada

About this study

Official title: Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria.

Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Conditions: Sexual Dysfunctions, Psychological
Being tested: flibanserin, flibanserin 50mg, flibanserin 100mg, placebo
Medical subject headings: Sexual Dysfunctions, Psychological

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

flibanserinDrug
flibanserin 25 mg b.i.d
flibanserin 50mgDrug
flibanserin 50mg qhs/b.i.d.
flibanserin 100mgDrug
flibanserin 50 mg b.i.d/100mg qhs
placeboDrug
placebo comparator

Study groups in NCT00360555
Study group	Role	What they receive
flibanserin	Experimental	flibanserin 25 mg b.i.d Receives: Drug: flibanserin 50mg
flibanserin 50mg	Experimental	flibanserin 50mg qhs/b.i.d Receives: Drug: flibanserin 100mg
flibanserin 100mg	Experimental	flibanserin 50mg b.i.d./100mg qhs Receives: Drug: placebo
placebo	Placebo comparator	placebo comparator Receives: Drug: flibanserin

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.
For endpoints collected on the eDiary, responses are accumulated on a monthly basis using the following algorithms.
For satisfying sexual events:
Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered)
Measured: baseline to 28 weeks
Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.
Change from baseline in the electronic diary (eDiary) Sexual Desire Monthly Total Score standardized to a 28-day period (score range 0-84). Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24. Patients were asked to record information daily in the eDiary throughout the trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read "Indicate your most intense level of sexual desire in the last 24 hours / since your last visit." Potential responses included "no," "low," "moderate," or "strong" and was scored 0-3, with 0 indicating no desire and 3 indicating the highest level of desire:
0 = No desire
1. = Low desire
2. = Moderate desire
3. = Strong desire
Measured: baseline to 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Jul 2006Mar 2008

First posted4 Aug 2006 (estimated)
Study startJul 2006
Primary completionMar 2008
Study completionMar 2008

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Sexual Dysfunctions, PsychologicalStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 1,584 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00360555
Sponsor's protocol ID: 511.75
Status last verified: Jun 2016
First submitted: 3 Aug 2006
Last updated: 27 Jun 2016
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes

Publications

Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R; DAISY trial investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012 Mar;9(3):793-804. doi: 10.1111/j.1743-6109.2011.02595.x. Epub 2012 Jan 12.
PubMed 22239862

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Not yet recruiting
HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
HIV Testing, STI
Recruiting
Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Not yet recruitingPhase 4
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
HIV Infections, Opioid Use Disorder
Recruiting
The Trans-Led Care Study
Substance Abuse, Substance Addiction

All Sexual Dysfunctions, Psychological trials

Study at a glance

From the registry record, last updated by the sponsor on 27 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America
ClinicalTrials.gov ID: NCT00360555
Acronym / sponsor ID: 511.75
Conditions: Sexual Dysfunctions, Psychological
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 1,584 participants (actual)
Lead sponsor: Sprout Pharmaceuticals, IncIndustry (pharma, biotech, devices)
Study start: Jul 2006
Primary completion: Mar 2008 (actual)
Study completion: Mar 2008 (actual)
First posted: 4 Aug 2006 (estimated)
Results: Posted 27 Jun 2016

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria.

Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 4

Arm	Type	Receives
flibanserin	Experimental	Drug: flibanserin 50mgflibanserin 25 mg b.i.d
flibanserin 50mg	Experimental	Drug: flibanserin 100mgflibanserin 50mg qhs/b.i.d
flibanserin 100mg	Experimental	Drug: placeboflibanserin 50mg b.i.d./100mg qhs
placebo	Placebo comparator	Drug: flibanserinplacebo comparator

Who may qualify

Ages: 18 to 55 years
Sex: Female only
Healthy volunteers: Not accepted
Age groups: Adult

Key inclusion criteria (12 listed)

Women who are 18 years of age and older.
Premenopausal women having regular menstrual periods who have HSDD (decreased sexual desire), generalized acquired type, according to DSM IV-TR criteria.
Patient must meet minimum cut-off scores on questionnaires relating to sexual functioning and sexual distress.
Patients must be willing to try to have sexual activity (e.g., any act involving direct genital stimulation) at least once monthly.
Patients must be willing and able to use an electronic diary on a daily basis (e.g., have access to a working land line telephone for daily data transmissions).

Key exclusion criteria (14 listed)

Patients who have taken any medication noted in the protocols List of Prohibited Medications within 30 days before screening.
Patients whose sexual function was affected (enhanced or worsened) in the investigators opinion by any medication within 30 days before the Screen Visit and anytime prior to the Baseline Visit.
Patients with a history of drug dependence or abuse within the past one year.
Patients with a history of multiple severe reactions (i.e., allergic or oversensitivity to usual doses) to drugs that affect the brain.
Patients with a history of participation in a trial of another investigational medication within one month prior to the Screen Visit, or participation in any previous clinical trial of flibanserin.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
flibanserinflibanserin 25 mg b.i.d	Drug	placebo
flibanserin 50mgflibanserin 50mg qhs/b.i.d.	Drug	flibanserin
flibanserin 100mgflibanserin 50 mg b.i.d/100mg qhs	Drug	flibanserin 50mg
placeboplacebo comparator	Drug	flibanserin 100mg

Primary outcome

Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.
Time frame: baseline to 28 weeks
For endpoints collected on the eDiary, responses are accumulated on a monthly basis using the following algorithms. For satisfying sexual events: Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered)
Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.
Time frame: baseline to 24 weeks
Change from baseline in the electronic diary (eDiary) Sexual Desire Monthly Total Score standardized to a 28-day period (score range 0-84). Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24. Patients were asked to record information daily in the eDiary throughout the trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read "Indicate your most intense level of sexual desire in the last 24 hours / since your last visit." Potential responses included "no," "low," "moderate," or "strong" and was scored 0-3, with 0 indicating no desire and 3 indicating the highest level of desire: 0 = No desire 1. = Low desire 2. = Moderate desire 3. = Strong desire

Results and safety

Results posted to the registry on 27 Jun 2016, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Flibanserin 25 mg b.i.d	396	274
Flibanserin 50mg Qhs/b.i.d	393	259
Flibanserin 50mg b.i.d./100mg Qhs	396	251
Placebo	399	287

Primary outcome: Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.

Time frame: baseline to 28 weeks. Mean (Standard Deviation). Unit: SSEs per 28 days

Measure	Flibanserin 25 mg b.i.d n = 376	Flibanserin 50mg Qhs/b.i.d n = 369	Flibanserin 50mg b.i.d./100mg Qhs n = 371	Placebo n = 381
Value	1.4 (3.5)	1.4 (3.4)	1.9 (5.3)	1.1 (3.4)

Population analysed: Participants who received at least one post-dose on-treatment efficacy assessment were included in the Full Analysis Set (FAS). Efficacy endpoints were analyzed primarily using the FAS.

Primary outcome: Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.

Time frame: baseline to 24 weeks. Least squares mean (Standard Error). Unit: units on a scale

Measure	Flibanserin 25 mg b.i.d n = 376	Flibanserin 50mg Qhs/b.i.d n = 369	Flibanserin 50mg b.i.d./100mg Qhs n = 371	Placebo n = 381
Value	7.9 (0.8)	8.8 (0.8)	8.5 (0.8)	6.8 (0.8)

Adverse events

Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Flibanserin 25 mg b.i.d	7 of 396 (1.8%)	168 of 396 (42.4%)	Not reported
Flibanserin 50mg Qhs/b.i.d	6 of 392 (1.5%)	293 of 392 (74.7%)	Not reported
Flibanserin 50mg b.i.d./100mg Qhs	3 of 395 (0.8%)	266 of 395 (67.3%)	Not reported
Placebo	8 of 398 (2%)	133 of 398 (33.4%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2016.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 22239862Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R; DAISY trial investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012 Mar;9(3):793-804. doi: 10.1111/j.1743-6109.2011.02595.x. Epub 2012 Jan 12.

Related trials for Sexual Dysfunctions, Psychological

Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Not yet recruiting
HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
HIV Testing, STI
Recruiting
Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Not yet recruitingPhase 4
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
HIV Infections, Opioid Use Disorder
Recruiting
The Trans-Led Care Study
Substance Abuse, Substance Addiction

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Boehringer Ingelheim study chair

Boehringer Ingelheim

77 sites in 2 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing flibanserin, flibanserin 50mg and flibanserin 100mg in people with Sexual Dysfunctions, Psychological, run by Sprout Pharmaceuticals, Inc at 77 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 77 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Jun 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary. (time frame: baseline to 28 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00360555, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2016.